Pharmacogenomics and Effective Treatment With Clopidogrel
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01611545 |
Recruitment Status :
Completed
First Posted : June 5, 2012
Last Update Posted : June 11, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Pharmacogenomics and Cardiovascular Events | Genetic: Pharmacogenomics |
Study Type : | Observational |
Actual Enrollment : | 130 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Can Pharmacogenomic Testing Improve Response and Avoid Adverse Effects With Clopidogrel Therapy? A Biospecimen Bank for Genetic and Genomic Investigation of Clopidogrel. |
Study Start Date : | June 2012 |
Actual Primary Completion Date : | January 2015 |
Actual Study Completion Date : | January 2015 |

Group/Cohort | Intervention/treatment |
---|---|
Clopidogrel
Patients taking or prescribed clopidogrel or under consideration Utilizing pharmacogenomics to determine the most effective treatment
|
Genetic: Pharmacogenomics
Utilizing pharmacogenomics to determine the most effective treatment
Other Name: Plavix |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Currently taking or prescribed Clopidogrel or under consideration
- Acute/interventionPatients of the Avera Heart Hospital
- Cardiology clinic patients with the Avera Heart Hospital and North Central Heart Institute
Exclusion Criteria:
- Unable to provide informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01611545
United States, South Dakota | |
Avera Institute for Human Genetics | |
Sioux Falls, South Dakota, United States, 57108 |
Principal Investigator: | Gareth Davies, PhD | Avera McKennan Hospital & University Health Center |
Publications:
Responsible Party: | Avera McKennan Hospital & University Health Center |
ClinicalTrials.gov Identifier: | NCT01611545 |
Other Study ID Numbers: |
AIHG-1410-Clopidogrel |
First Posted: | June 5, 2012 Key Record Dates |
Last Update Posted: | June 11, 2015 |
Last Verified: | June 2015 |
Pharmacogenomics Pharmacogenetics Clopidogrel Plavix |